argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-04-28 08:31 |
argenx Management to Present at Upcoming Virtual Investor Conferences
|
English | 20.6 KB | ||
| 2021-04-07 08:47 |
argenx SE announces 2021 AGM
|
English | 28.6 KB | ||
| 2021-04-07 08:47 |
argenx SE announces 2021 AGM
|
English | 9.5 MB | ||
| 2021-04-02 09:06 | English | 9.5 MB | |||
| 2021-03-31 08:16 |
argenx announces Annual General Meeting of Shareholders on May 11, 2021
|
English | 191.4 KB | ||
| 2021-03-04 08:40 |
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Bus…
|
English | 344.4 KB | ||
| 2021-03-04 08:40 |
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Bus…
|
English | 125.5 KB | ||
| 2021-03-02 08:22 |
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatmen…
|
English | 41.2 KB | ||
| 2021-02-25 08:26 |
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business U…
|
English | 18.5 KB | ||
| 2021-02-08 08:00 |
argenx announces closing of global offering
|
English | 36.0 KB | ||
| 2021-02-04 08:24 |
argenx announces full exercise of underwriters’ option to purchase additional A…
|
English | 48.9 KB | ||
| 2021-02-03 08:37 |
argenx raises $1.0 billion in gross proceeds in a global offering
|
English | 55.9 KB | ||
| 2021-02-03 08:36 |
argenx Issues Statement Concerning Efgartigimod
|
English | 30.6 KB | ||
| 2021-02-02 08:46 |
argenx announces launch of proposed global offering
|
English | 60.5 KB | ||
| 2021-02-01 09:06 |
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Infla…
|
English | 50.5 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
